GRPH Stock Overview
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Graphite Bio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$22.26 |
52 Week High | US$22.62 |
52 Week Low | US$2.01 |
Beta | 0.20 |
1 Month Change | 654.58% |
3 Month Change | 831.38% |
1 Year Change | 861.56% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 20.32% |
Recent News & Updates
Recent updates
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
Sep 20We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely
Jun 02Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?
Feb 01Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
Oct 05Graphite Bio doses first patient with GPH101 for sickle cell disease
Aug 11Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?
Jun 22Graphite Bio: Selling For Much Less Than Net Cash
May 25Graphite Bio: An Important Stock To Track In The Gene Editing Space
Nov 18Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans
Sep 25Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr
Aug 30Shareholder Returns
GRPH | US Biotechs | US Market | |
---|---|---|---|
7D | 539.7% | 0.9% | 0.2% |
1Y | 861.6% | 11.0% | 28.1% |
Return vs Industry: GRPH exceeded the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: GRPH exceeded the US Market which returned 31.2% over the past year.
Price Volatility
GRPH volatility | |
---|---|
GRPH Average Weekly Movement | 166.3% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRPH's share price has been volatile over the past 3 months.
Volatility Over Time: GRPH's weekly volatility has increased from 82% to 166% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 6 | Kim Drapkin | https://graphitebio.com |
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
Graphite Bio, Inc. Fundamentals Summary
GRPH fundamental statistics | |
---|---|
Market cap | US$190.43m |
Earnings (TTM) | -US$124.65m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.4x
P/E RatioIs GRPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GRPH income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$124.65m |
Earnings | -US$124.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.14 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did GRPH perform over the long term?
See historical performance and comparison